For a menopausal woman with treatment‑resistant moderate‑to‑severe depression or anxiety, what are the recommended ketamine dosing regimens, contraindications, monitoring requirements, and alternative treatment options?

Ketamine for Mental Health During Menopause

For menopausal women with treatment-resistant moderate-to-severe depression or anxiety, ketamine or esketamine should be considered only after failure of at least 2 adequate antidepressant trials, using IV ketamine at 0.5 mg/kg infused over 40 minutes or intranasal esketamine with twice-weekly dosing as augmentation to ongoing oral antidepressants. 1

When to Consider Ketamine/Esketamine

The 2022 VA/DoD Clinical Practice Guideline represents a significant shift, now recommending ketamine or esketamine as a third-line treatment option specifically for patients who have not responded to several adequate pharmacologic trials 1. This is not a first-line treatment—you must document failure of at least 2 prior adequate antidepressant trials before considering this option 1.

Evidence Base

• Single-dose IV ketamine shows significant improvement in depressive symptoms within 24 hours, with effects persisting 3-4 days 1
• When added to ongoing antidepressant treatment, benefits may extend to 7 days, but monotherapy shows no significant difference at 7 days 1
• Esketamine (intranasal) as augmentation therapy improves depressive symptoms and remission rates up to 28 days with twice-weekly dosing 1
• Both agents also show efficacy for anxiety symptoms in the context of treatment-resistant depression 2

Recommended Dosing Regimens

IV Ketamine (Racemic)

• Initial dose: 0.5 mg/kg infused over 40-45 minutes 1, 3, 4
• Acute series: 6 infusions over 2-3 weeks (typically twice weekly) 5, 6, 4
• Dose escalation option: May increase to 0.75 mg/kg for subsequent infusions if inadequate response 5
• Maintenance: Case-by-case basis only, with careful risk-benefit assessment 4

Intranasal Esketamine

• Dosing: Twice-weekly as augmentation to ongoing oral antidepressant 1
• Duration: Up to 28 days for acute treatment, with evidence supporting longer-term maintenance 1
• REMS requirements: Mandatory 2-hour post-treatment monitoring, pharmacy and healthcare setting certification required 1

Alternative Routes (Limited Evidence)

• Subcutaneous ketamine: 0.5 mg/kg, maximum 6 treatments twice weekly—shows promise but Level 3-4 evidence only 6, 4
• Oral formulations: Should be limited to specialists with ketamine-prescribing expertise at tertiary centers due to misuse/diversion risk 4

Absolute Contraindications

Do not use ketamine/esketamine in patients with:

• Significant cardiovascular disease where blood pressure elevation would be hazardous 3, 7
• Uncontrolled hypertension 7
• Known hypersensitivity to ketamine or excipients 3
• Active substance use disorder (relative contraindication requiring careful assessment) 8, 4

Mandatory Monitoring Requirements

Pre-Treatment Assessment

• Cardiovascular screening: Blood pressure measurement, ECG if indicated, assess for conditions where BP elevation is dangerous 7, 8
• Psychiatric evaluation: Confirm treatment-resistant depression diagnosis, document prior medication failures, assess suicide risk 8, 4
• Medical clearance: Screen for contraindications, review concomitant medications 8

During Treatment

• Vital signs: Monitor blood pressure and pulse every 15-30 minutes during infusion and for 2 hours post-treatment 3, 7, 8
  • Expect SBP/DBP increases of 10-50% above baseline, peaking at 30-50 minutes 7
  • If blood pressure remains elevated, provide acute management; hypertensive crisis requires emergency care 7
• Dissociative symptoms: Common but transient; minimize verbal, tactile, and visual stimulation during recovery 3, 8
• Respiratory status: Maintain adequate oxygenation and ventilation 3

Post-Treatment

• Recovery period: Minimum 2 hours observation (mandatory for esketamine REMS) 1
• Activity restrictions: No driving, operating machinery, or hazardous activities for 24 hours 3
• Symptom monitoring: Assess depressive/anxiety symptoms using standardized scales (MADRS, QIDS-SR) 6, 8

Critical Caveats for Menopausal Women

Specific Considerations

While the evidence base doesn't specifically address menopausal women as a distinct population, several factors warrant attention:

• Cardiovascular risk: Menopause increases cardiovascular risk; ketamine's transient hypertensive effects (10-50% BP elevation) require particularly careful monitoring 7
• Hormone interactions: No specific evidence exists regarding interactions with hormone replacement therapy—proceed with standard monitoring
• Comorbid anxiety: Ketamine shows efficacy for anxiety symptoms in depression, which may be particularly relevant given anxiety prevalence during menopause 2

Common Pitfalls to Avoid

1. Using as first-line treatment: This is explicitly not recommended—document adequate trials of at least 2 antidepressants first 1
2. Inadequate monitoring: Blood pressure monitoring is non-negotiable; transient elevations are expected but require active management 7
3. Expecting sustained monotherapy effects: Effects without maintenance are typically short-lived (days to 1-2 weeks); plan for either repeated treatments or transition to other therapies 1, 5
4. Ignoring REMS requirements for esketamine: These are mandatory regulatory requirements, not optional 1

Alternative Treatment Options

Before considering ketamine, ensure adequate trials of:

• Multiple antidepressant classes at therapeutic doses for adequate duration
• Augmentation strategies: Lithium, thyroid hormone, atypical antipsychotics
• Psychotherapy: Cognitive-behavioral therapy, interpersonal therapy
• Other neuromodulation: Repetitive transcranial magnetic stimulation (rTMS) if available 1

Evidence Limitations

The evidence has significant gaps:

• Ketamine lacks long-term efficacy and safety data beyond 7 days for single doses 1
• Maintenance treatment evidence is limited (Level 3) 4
• No specific studies in menopausal populations
• Risk of dependence with repeated use requires ongoing assessment 8, 4

The recommendation reflects a balance: consistent short-term benefit versus limited long-term data and potential adverse effects 1. Use ketamine/esketamine as a bridge or acute intervention rather than indefinite maintenance therapy unless absolutely necessary with documented ongoing benefit.